Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease (SUN-AK)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00951834|
Recruitment Status : Completed
First Posted : August 4, 2009
Last Update Posted : December 22, 2017
EGCG has shown a neuroprotective effect in cell-experimental and animal studies. The neuroprotective mechanism of EGCG probably bases - besides the known antioxidant effect - amongst others on the modulation of several signal transduction pathways, the influence on the expression of genes which regulate cell survival resp. programmed cell death, as well as the modulation of the mitochondrial function. In different Alzheimer models EGCG seems to cause an induction of alpha-secretase and the endothelin-converting-enzyme, as well as to prevent the aggregation of beta-amyloid to toxic oligomers through the direct binding to the unfolded peptide.
The investigators therefore expect EGCG to have a positive influence on the course of the Alzheimer´s Disease.
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer's Disease||Drug: Epigallocatechin-Gallate Drug: Placebo||Phase 2 Phase 3|
Alzheimer's disease (AD) is a progressive dementia characterised by an ongoing loss of memory function and of at least one additional cognitive domain resulting in impairment of daily life functioning. Treatment of diseases such as diabetes mellitus, fractures and cardiovascular diseases is more expensive and complicated in patients with dementia compared to those without. The yearly costs for treatment and care of AD patients in the US are estimated to exceed 100 billion USD. Life expectancy is reported to be about 10 years after establishment of the diagnosis and is significantly reduced compared to non-demented subjects of similar age and socio-economic status.
Age is the most relevant risk factor for AD, followed by genetic factors. Prevalence is less than 1% amongst individuals aged 50-60, but is reported to double every 5 years beyond the age of 60. The prevalence exceeds 30% in the age of 85-90.
The only standard therapy for AD are acetylcholine-esterase inhibitors (AchEI; donepezil, galantamine, rivastigmine). AchEI exhibit a temporary stabilizing mild effect on the progression of AD. Conversion rates from "mild cognitive impairment" to AD do not seem to be beneficially influenced by AchEI. A high percentage of premature study withdrawals owing to adverse events has been observed in AchEI studies published to date. The questionable benefit may further be outweighed by high costs of the AchEI.
Therefore, there is a necessity for the development of more efficacious and less expensive disease-modifying drugs with a better safety and tolerability profile. EGCG is a promising compound which has proven efficacious in AD animal models and which has shown an excellent tolerability in our 18-month clinical trial on Multiple Sclerosis currently being performed at our institution (SuniMS study, NCT00525668).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||21 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease|
|Study Start Date :||October 2009|
|Primary Completion Date :||February 2015|
|Study Completion Date :||February 2015|
add-on to Donepezil.
Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg:
Other Name: Sunphenon EGCG
Placebo Comparator: Placebo
add-on to Donepezil.
- ADAS-COG (Score 0-70) (Baseline to treatment) [ Time Frame: 18 months ]
- Safety and tolerability of the verum [ Time Frame: 18 months ]
- MMSE (Score 0-30) after 18 months compared to baseline [ Time Frame: 18 months ]
- Time to hospitalisation and Time to death related to AD [ Time Frame: 18 months ]
- Brain atrophy assessed by brain MRI [ Time Frame: 18 months ]
- Baseline-ADAS-COG and Baseline-MMSE as covariates [ Time Frame: 18 months ]
- CIBIC+ and WHO-QOL-Bref [ Time Frame: 18 months ]
- Trail Making Test and MVGT [ Time Frame: 18 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00951834
|Charite University Medicine Berlin|
|Berlin, Germany, 10117|
|Charité Universitätsmedizin Berlin Klinik für Psychiatrie und Psychotherapie|
|Berlin, Germany, 10117|
|Klinik für Neurologie|
|Ulm, Germany, 89081|
|Principal Investigator:||Friedemann Paul, MD||Charite University Medicine Berlin, NeuroCure|